Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Boehringer Ingelheim’s novel project transfer program enables fast track to launch for biopharmaceuticals

Boehringer Ingelheim
Posted on: 01 Oct 12

Ingelheim, Germany, 1 October 2012 - Boehringer Ingelheim Biopharmaceuticals has installed a fast track process transfer to commercial scale.

Companies that outsource their biopharmaceutical phase III projects to Boehringer Ingelheim can now benefit from its proven ‘Smart-to-Launch’ processes that can shorten the timelines from kick-off to drug substance availability and completion of the CMC regulatory package (Chemistry, Manufacturing & Controls) to just 8 months and 15 months, respectively, without compromises on quality. Boehringer Ingelheim’s fill and finish service can be seamlessly integrated to deliver drug products to customers as fast as 17 months from kick off to completion of CMC package. ‘Smart-to-Launch’ is available for both mammalian and microbial projects.

“We have developed ‘Smart-to-Launch’ over the last years and have already received positive customer feedback”, commented Uwe Buecheler, Senior Vice President Global Biopharma Operations at Boehringer Ingelheim. “’Smart-to-Launch’ significantly speeds up project transfers, scale up, process validation and clinical phase III supplies and can bring our customers cost-and timeline advantages.”

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion Euro.

Boehringer Ingelheim Biopharma Contract Manufacturing is now represented by its new brand Boehringer Ingelheim BioXcellence™. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought 19 biopharmaceutical products to market. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria) and Fremont (USA).

Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.

For more information:

Editor's Details

Boehringer Ingelheim
Boehringer Ingelheim

Last updated on: 01/10/2012

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.